Amarin Co. plc (NASDAQ:AMRN) Shares Sold by SVB Wealth LLC

SVB Wealth LLC decreased its position in shares of Amarin Co. plc (NASDAQ:AMRN) by 33.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 40,000 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the period. SVB Wealth LLC’s holdings in Amarin were worth $36,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AMRN. BNP Paribas Financial Markets raised its stake in Amarin by 104.8% in the first quarter. BNP Paribas Financial Markets now owns 932,173 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 476,996 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Amarin by 351.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 34,725 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in Amarin by 100.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 23,313 shares in the last quarter. LCM Capital Management Inc boosted its position in Amarin by 5.1% during the fourth quarter. LCM Capital Management Inc now owns 740,159 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 36,000 shares in the last quarter. Finally, Hayek Kallen Investment Management raised its position in Amarin by 63.3% during the fourth quarter. Hayek Kallen Investment Management now owns 1,016,760 shares of the biopharmaceutical company’s stock worth $885,000 after acquiring an additional 394,117 shares during the last quarter. 22.25% of the stock is currently owned by hedge funds and other institutional investors.

Amarin Stock Down 12.9 %

Shares of NASDAQ:AMRN opened at $0.68 on Thursday. Amarin Co. plc has a fifty-two week low of $0.63 and a fifty-two week high of $1.37. The firm has a 50-day simple moving average of $0.76 and a 200 day simple moving average of $0.93.

Amarin (NASDAQ:AMRN) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. The firm had revenue of $56.52 million for the quarter, compared to analysts’ expectations of $51.34 million. During the same quarter last year, the company earned ($0.04) EPS. As a group, analysts expect that Amarin Co. plc will post -0.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. StockNews.com lowered Amarin from a “buy” rating to a “hold” rating in a research note on Thursday, July 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research report on Tuesday, June 18th.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.